China Hastens to Establish Regulatory Biosimilars Framework
By Shannon Ellis
Monday, August 26, 2013
SHANGHAI – Looking to lower costs and facilitate better health care outcomes, China is stepping up efforts to develop a regulatory framework and a market for biosimilars. One way or another, China has been producing biosimilars for about two decades.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.